Antibiotic Resistance Market Report: Trends, Forecast and Competitive Analysis to 2030

Antibiotic Resistance Trends and Forecast

The future of the global antibiotic resistance market looks promising with opportunities in the hospital pharmacie, retail pharmacie and online pharmacie markets. The global antibiotic resistance market is expected to reach an estimated $12.2 billion by 2030 with a CAGR of 5.9% from 2024 to 2030. The major drivers for this market are increasing prevalence of antibiotic and growing government and non-government bodies involvement in the development of novel therapies.

A more than 150-page report is developed to help in your business decisions.

Antibiotic Resistance by Segment

The study includes a forecast for the global antibiotic resistance by disease, pathogen, distribution channel, mechanism of action, and region.

Antibiotic Resistance Market by Disease [Shipment Analysis by Value from 2018 to 2030]:

• cUTI (Complicated Urinary Tract Infections)
• CDI (Clostridioides Difficile Infection)
• ABSSSI (Acute Bacterial Skin and Skin Structure Infections)
• HABP (Hospital-Acquired Bacterial Pneumonia)
• CABP (Community-Acquired Pneumonia)
• cIAI (Complicated Intra-Abdominal Infection)
• Others

Antibiotic Resistance Market by Pathogen [Shipment Analysis by Value from 2018 to 2030]:

• E. Coli
• K. Pneumoniae
• P. Aeruginosa
• S. Aureus
• A. Baumannii
• S. Pneumoniae
• Others

Antibiotic Resistance Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Antibiotic Resistance Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Others

Antibiotic Resistance Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Antibiotic Resistance Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antibiotic resistance companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antibiotic resistance companies profiled in this report include-

• Melinta
• Basilea Pharmaceutical
• Tetraphase Pharmaceuticals
• Theravance Biopharma
• WOCKHARDT

Antibiotic Resistance Market Insights

Lucintel forecasts that cUTI (complicated urinary tract infection) will remain the largest segment over the forecast period due to existence of a robust product development pipeline.

Within this market, hospital pharmacie will remain the largest segment as it plays a vital role in overseeing drug formularies, tracking resistance patterns, delivering education, and guaranteeing medication safety.

North America will remain the largest region over the forecast period due to increasing number of government programs and mandatory insurance policies in the region.

Features of the Global Antibiotic Resistance Market

Market Size Estimates: Antibiotic resistance market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antibiotic resistance market size by various segments, such as by disease, pathogen, distribution channel, mechanism of action, and region in terms of value ($B).

Regional Analysis: Antibiotic resistance market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, pathogens, distribution channels, mechanism of actions, and regions for the antibiotic resistance market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antibiotic resistance market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the antibiotic resistance market size?

Answer: The global antibiotic resistance market is expected to reach an estimated $12.2 billion by 2030.

Q2. What is the growth forecast for antibiotic resistance market?

Answer: The global antibiotic resistance market is expected to grow with a CAGR of 5.9% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the antibiotic resistance market?

Answer: The major drivers for this market are increasing prevalence of antibiotic and growing government and non-government bodies involvement in the development of novel therapies.

Q4. What are the major segments for antibiotic resistance market?

Answer: The future of the antibiotic resistance market looks promising with opportunities in the hospital pharmacie, retail pharmacie and online pharmacie markets.

Q5. Who are the key antibiotic resistance market companies?

Answer: Some of the key antibiotic resistance companies are as follows:

• Melinta
• Basilea Pharmaceutical
• Tetraphase Pharmaceuticals
• Theravance Biopharma
• WOCKHARDT

Q6. Which antibiotic resistance market segment will be the largest in future?

Answer: Lucintel forecasts that cUTI (complicated urinary tract infection) will remain the largest segment over the forecast period due to existence of a robust product development pipeline.

Q7. In antibiotic resistance market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing number of government programs and mandatory insurance policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the antibiotic resistance market by disease (cUTI (complicated urinary tract infections), CDI (clostridioides difficile infection), ABSSSI (acute bacterial skin and skin structure infections), HABP (hospital-acquired bacterial pneumonia), CABP (community-acquired pneumonia), CIAI (complicated intra-abdominal infection), and others), pathogen (e. coli, k. pneumoniae, p. aeruginosa, s. aureus, a. baumannii, s. pneumoniae, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), mechanism of action (protein synthesis inhibitors, cell wall synthesis inhibitors, rna synthesis inhibitors, dna synthesis inhibitors, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?